Dogwood Therapeutics to Announce Q3 2025 Financial Results

Dogwood Therapeutics, Inc., a biotechnology company specializing in novel pain and neuropathy treatments, is set to disclose its financial outcomes for the third quarter of 2025. The announcement will occur on Thursday, November 6, before financial markets open. This event marks a significant step for the Nasdaq-listed company as it continues advancing its pharmaceutical pipeline.

Dogwood's development efforts are currently centered around two primary drug candidates: Halneuron® and SP16 IV. Halneuron® is in the Phase 2b stage, focusing on treating neuropathy pain linked to chemotherapy. Notably, it carries a fast-track designation by the FDA, aiming to offer non-opioid pain relief. Meanwhile, SP16 IV, also showing promise for treating neuropathy, is preparing for a Phase 1b trial, supported by the National Cancer Institute.